Skip to Content

Utilizing ST2 in the Management of Heart Failure Patients


ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity, and renal impairment. ST2, Serum is a non-invasive test that measures soluble ST2 in the blood, which can aid physicians in risk assessment of chronic heart failure patients. Critical Diagnostics, the developer of the ST2 test, hosted a live webinar that highlights real-life clinical case studies where ST2 provides incremental information above existing clinical tools.

To view this webinar, click here.

Alyssa Frank

Alyssa Frank

Alyssa Frank is a Marketing Segment Manager at Mayo Clinic Laboratories. She leads marketing strategies for product management and specialty testing. Alyssa has worked at Mayo Clinic since 2015.